Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Apr;23(4):687-95.
doi: 10.1681/ASN.2011070674. Epub 2012 Feb 23.

Survival with three-times weekly in-center nocturnal versus conventional hemodialysis

Eduardo Lacson Jr  1 , Jianglin Xu, Rita S Suri, Gihad Nesrallah, Robert Lindsay, Amit X Garg, Keith Lester, Norma Ofsthun, Michael Lazarus, Raymond M Hakim
Affiliations
Comparative Study

Survival with three-times weekly in-center nocturnal versus conventional hemodialysis

Eduardo Lacson Jr et al. J Am Soc Nephrol. 2012 Apr.

Abstract

Whether the duration of hemodialysis treatments improves outcomes remains controversial. Here, we evaluated survival and clinical changes associated with converting from conventional hemodialysis (mean=3.75 h/treatment) to in-center nocturnal hemodialysis (mean=7.85 h/treatment). All 959 consecutive patients who initiated nocturnal hemodialysis for the first time in 77 Fresenius Medical Care facilities during 2006 and 2007 were eligible. We used Cox models to compare risk for mortality during 2 years of follow-up in a 1:3 propensity score-matched cohort of 746 nocturnal and 2062 control patients on conventional hemodialysis. Two-year mortality was 19% among nocturnal hemodialysis patients compared with 27% among conventional patients. Nocturnal hemodialysis associated with a 25% reduction in the risk for death after adjustment for age, body mass index, and dialysis vintage (hazard ratio=0.75, 95% confidence interval=0.61-0.91, P=0.004). With respect to clinical features, interdialytic weight gain, albumin, hemoglobin, dialysis dose, and calcium increased on nocturnal therapy, whereas postdialysis weight, predialysis systolic blood pressure, ultrafiltration rate, phosphorus, and white blood cell count declined (all P<0.001). In summary, notwithstanding the possibility of residual selection bias, conversion to treatment with nocturnal hemodialysis associates with favorable clinical features, laboratory biomarkers, and improved survival compared with propensity score-matched controls. The potential impact of extended treatment time on clinical outcomes while maintaining a three times per week hemodialysis schedule requires evaluation in future clinical trials.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Enrollment algorithm. Patient flow into the study.
Figure 2.
Figure 2.
Enhanced INHD survival. Kaplan–Meier 2-year survival curves comparing patients on INHD (broken line) with patients on CHD (solid line).
Figure 3.
Figure 3.
Enhanced adjusted INHD survival. Results from Cox proportional hazard models comparing time to death from patients treated by INHD with patients on CHD.
Figure 4.
Figure 4.
Improved clinical features on INHD. Changes in (A) dialysis dose, (B) ultrafiltration rate, (C) postdialysis weight, (D) predialysis systolic blood pressure, (E) interdialytic weight gain, and (F) intradialytic weight loss associated with conversion from CHD to INHD from baseline (period 1), first 90 days (period 2), and days 91–180 (period 3) along with period prevalent propensity score-matched controls that were treated solely with CHD. (INHD: n=435; CHD: n=1219).
Figure 5.
Figure 5.
Improved biomarkers on INHD. Laboratory changes for (A) albumin, (B) hemoglobin, (C) phosphorus, (D) calcium, and (E) white blood cell count associated with conversion from CHD to INHD from baseline (period 1), first 90 days (period 2), and days 91–180 (period 3) along with period prevalent propensity score–matched controls that were treated solely with CHD. (INHD: n=435; CHD: n=1219).
Figure 6.
Figure 6.
Long-term maintenance INHD therapy. INHD technique survival over 2 years.
See this image and copyright information in PMC

Comment in

References

    1. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010–2019, 2002 - PubMed
    1. Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Kliger AS. Frequent Hemodialysis Network Trial Group: Frequent Hemodialysis Network (FHN) randomized trials: Study design. Kidney Int 71: 349–359, 2007 - PubMed
    1. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS. FHN Trial Group: In-center hemodialysis six times per week versus three times per week. N Engl J Med 363: 2287–2300, 2010 - PMC - PubMed
    1. Ramkumar N, Beddhu S, Eggers P, Pappas LM, Cheung AK: Patient preferences for in-center intense hemodialysis. Hemodial Int 9: 281–295, 2005 - PubMed
    1. Centers for Medicare & Medicaid Services (CMS), HHS : Medicare program; End-stage renal disease prospective payment system. Final rule. Fed Regist 75: 49029–49214, 2010 - PubMed